home All News open_in_new Full Article

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the “Offering”) of 12,727,273 common shares […]


today 1 week ago attach_file Economics

attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Society
attach_file Politics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Economics
attach_file Other


ID: 3209600405
Add Watch Country

arrow_drop_down